Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-Term Debt repayments (2021 - 2022)

Aytu Biopharma (AYTU) has disclosed Short-Term Debt repayments for 2 consecutive years, with $30.5 million as the latest value for Q3 2022.

  • Quarterly Short-Term Debt repayments fell 33.11% to $30.5 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $163.5 million through Sep 2022, changed N/A year-over-year, with the annual reading at $156.4 million for FY2022, 189.66% up from the prior year.
  • Short-Term Debt repayments for Q3 2022 was $30.5 million at Aytu Biopharma, down from $39.3 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $48.0 million in Q2 2021, with the low at $30.5 million in Q3 2022.